GlassScriptPhysician profile
Andrew B Reisman
NPI 1053391490
$17,533.89
in general payments reported to CMS, 2019-2025
58 companies · $930 in 2025
The $930 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,392 · 2020: $2,823 · 2021: $3,153 · 2022: $3,017 · 2023: $2,884 · 2024: $2,334 · 2025: $930.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,033 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,032.80 |
| Education | $116.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,393.21 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $2,027.35 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $1,261.38 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,181.65 | 2021-2025 | |
| Amgen INC. | $1,167.10 | 2019-2024 | Evenity, Otezla, Repatha |
| Abbvie INC. | $1,037.47 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $787.99 | 2019-2025 | |
| Amarin Pharma, INC. | $770.33 | 2019-2021 | |
| Astellas Pharma US INC | $646.76 | 2019-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $516.38 | 2019-2025 | Shingrix, Bexsero, Arexvy |
| Esperion Therapeutics, INC. | $508.05 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $499.82 | 2019-2023 | Trintellix |
| Merck Sharp & Dohme LLC | $492.90 | 2019-2023 | Belsomra, Steglatro, Januvia |
| Otsuka America Pharmaceutical, INC. | $325.88 | 2019-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $318.54 | 2019-2025 | Jardiance |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Reisman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.